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Context: Lipoid congenital adrenal hyperplasia (CAH) is the most
severe form of CAH leading to impaired production of all adrenal and
gonadal steroids. Mutations in the gene encoding steroidogenic acute
regulatory protein (StAR) cause lipoid CAH.
Objective: We investigated three unrelated patients of Swiss ances-
try who all carried novel mutations in the StAR gene. All three sub-
jects were phenotypic females with absent Mu ¨llerian derivatives,
46,XY karyotype, and presented with adrenal failure.
Methods and Results: StAR gene analysis showed that one patient
was homozygous and the other two were heterozygous for the novel
missense mutation L260P. Of the heterozygote patients, one carried
the novel missense mutation L157P and one had a novel frameshift
mutation (629–630delCT) on the second allele. The functional ability
of all three StAR mutations to promote pregnenolone production was
severely attenuated in COS-1 cells transfected with the cholesterol
side-chaincleavagesystemandmutantvs.wild-typeStARexpression
vectors.
Conclusions: These cases highlight the importance of StAR-depen-
dent steroidogenesis during fetal development and early infancy; ex-
pand the geographic distribution of this condition; and finally estab-
lish a new, prevalent StAR mutation (L260P) for the Swiss
population. (J Clin Endocrinol Metab 90: 5304–5308, 2005)
L
IPOID CONGENITAL ADRENAL hyperplasia (CAH)
wasoriginallydescribedin1955byPraderandGurtner
(1) in a Swiss 46, XY baby girl presenting with severe salt
wasting due to adrenal insufficiency and female external
genitalia but male gonads and adrenocortical hyperplasia on
autopsy. Lipoid CAH is probably the severest form of CAH,
impairing production of both adrenal and gonadal steroids
(2), and results from mutations in the gene encoding steroi-
dogenic acute regulatory protein (StAR) (3). StAR fosters the
transport of cholesterol into the mitochondria, in which cho-
lesterol is converted to pregnenolone by the P450 side-chain
cleavage-adrenodoxin-adrenodoxin reductase system (2–4).
Patients with lipoid CAH present with primary adrenal fail-
ureininfancy.Theiradrenalglandsareenlargedandcontain
lipoid deposits, reflecting cytoplasmic cholesterol accumu-
lation of cholesterol after prolonged ACTH stimulation (2).
In addition, impaired testosterone biosynthesis prevents vir-
ilization in karyotypic males (46, XY) (2).
Todate,morethan35StARmutationshavebeendescribed
in more than 70 patients, predominantly from Japan, Korea,
and Arabic countries (5–8). However, genetic diagnosis of
the Swiss patient with lipoid CAH originally described by
Prader was never made.
We report three patients of Swiss ancestry with lipoid
CAH in whom we found three novel StAR mutations. One
of them, identified in all patients, establishes a new, preva-
lent StAR mutation for the Swiss population.
Patients and Methods
Mutation analysis
After obtaining informed consent, DNA was extracted from periph-
eral blood leukocytes (9). Direct sequencing of the StAR gene was per-
formed as described previously (ABI 373A DNA analyzer; PerkinElmer,
Branchberg, NJ) (10).
Microsatellite analysis
Two microsatellites, D8S2331 and D8S536 (AFM265zf9), were used to
search for a common ancestral allele carrying the L260P StAR mutation.
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5304Oligonucleotide sequences and PCR conditions were obtained from the
CEPH genotype database (http:/ /www.cephb.fr/cephdb/).
Functional assay
Vectors expressing cDNAs of wild-type StAR and the fusion protein
P450 side-chain cleavage/adrenodoxin/adrenodoxin reductase (F2)
were a generous gift of Walter L. Miller (Department of Pediatrics,
University of California San Francisco, San Francisco, CA) (3, 11). Mu-
tant StAR cDNA expression vectors were constructed by PCR-based,
site-directed mutagenesis. All mutants were confirmed by direct se-
quencing. Functional analysis of the mutants was performed as de-
scribed previously (3), using MultiCalc software (PerkinElmer).
Structural modeling
The positions of the two mutated leucines, L157 and L260, were
mapped onto the crystal structure of the StAR-related lipid transfer
(START) domain of human MLN64 [protein database reference ID:
1EM2 (12)] using DS ViewerPro 5.0 software (Accelrys Inc., San Diego,
CA).PreviouslyreportedStARmissensemutationswereincludedinthe
model for comparison.
Case reports
Patient 1. This 46, XY girl was a single child of a nonconsanguineous
Swiss couple. She was delivered at term by cesarean section [birth
weight 2360 g (3.0 sd); length 47 cm (2.0 sd)]. At 5 months of age, she
wasreferredtothehospitalwithvomiting.Shewasdehydrated,andher
weight was 5240 g (P3) and height 63.5 cm (P25). She had normal female
external genitalia, without virilization, but was hyperpigmented. Ingui-
nal gonads were palpable. Laboratory investigations revealed severe
hypocortisolemia and grossly elevated ACTH and plasma renin activity
consistent with primary adrenal insufficiency (Table 1). Plasma steroids
remained low or undetectable after ACTH stimulation. Gonads were
removed and laparoscopy showed no Mu ¨llerian structures. Treatment
with hydrocortisone and fludrocortisone was started and resulted in
normal growth and development. Estrogens were started at 12 yr of age
to induce breast development. Pubic and axillary hair remained absent,
reflecting impaired adrenal and gonadal androgen production. The pa-
tient is now 27 yr old and healthy. She has a heterosexual orientation.
Patient 2. This patient was a full-term 46, XY baby girl born to a non-
consanguineousSwisscouple.Herbirthweightwas2930g(1.6sd)and
length 49 cm (0.6 sd). At 2.5 months of age, she was admitted with
failure to thrive. Physical examination revealed normal female external
genitalia and hyperpigmentation. Laboratory investigations revealed
severesaltwastingandlowserumcortisol.Magneticresonanceimaging
showed inguinal gonads but no Mu ¨llerian structures. The adrenals were
of normal size. Hydrocortisone and fludrocortisone replacement were
started.Thegirlisnow3.5yroldandshowsnormalphysicalandmental
development.
Patient 3. This 46, XY term baby was 3920 g (2.0 sd) at birth and had
normal female external genitalia. She was the third child of a noncon-
sanguineous French couple with Swiss ancestry. At the age of 3.5
months,shewasadmittedwithvomitingandapathyduringamildviral
infection. Hyperpigmentation of the skin-fold areas was noted. Ultra-
sound and computed tomography scan revealed gonads but no uterus.
Laboratory investigations were consistent with severe primary adrenal
insufficiency (Table 1). She recovered quickly after glucocorticoid and
mineralocorticoid replacement and, at 9 yr of age, is developing
normally.
Results
Mutation analysis
Because of severe, primary adrenal insufficiency, sex re-
versal with female external genitalia and impaired adrenal
and gonadal steroid hormone production, all three 46, XY
patients were analyzed for genetic defects in the StAR pro-
tein (Fig. 1).
Patient 1 harbored a novel homozygous missense muta-
tion L260P in exon 7 (T779 to C) (Fig. 1B). In patient 2, the
same L260P mutation was found on one allele, but the other
allelehadaL157Pmissensechange(T470toC)inexon5.Her
father is heterozygote for L260P and her mother heterozy-
gote for L157P. Patient 3 also had a L260P mutation on one
allele, combined with a 2-bp deletion in exon 5 (C629, T630)
on the other allele, which leads to a frame shift and prema-
ture stop at amino acid 235 (Fig. 1B). This patient shared
L260P with the father and 629–630delCT with the mother.
All three StAR mutations are novel. The identification of a
L260P change in all three patients indicates that this might
be a common mutation in the Swiss population.
Microsatellite analysis
Because no intragenic polymorphisms of the StAR gene
wereidentifiedinourpopulation,twomicrosatellitemarkers
were used to search for a common origin of the L260P StAR
TABLE 1. Biochemical characteristics of patients at diagnosis of adrenal insufficiency
Normal range (1–6 months) Patient 1 Patient 2 Patient 3
Age (months) 5.5 2.5 3.5
Sodium 129–143 mmol/liter 124 121 114
Potassium 3.7–5.8 mmol/liter 8.4 6.4 9.6
Glucose 50–88 mg/dl 22 31
(2.8–4.9 mmol/liter) (1.2) (1.7)
ACTH 9–52 pg/ml 2000 1362
(2–11 pmol/liter) (440) (300)
Cortisol 5–25 g/dl 1 2.8
(140–690 nmol/liter) (22) (78)
17-Hydroxyprogesterone 3.3–89 ng/dl 9.9 6.9
(0.1–2.7 nmol/liter) (0.3) (0.21)
Progesterone 6.3–50 ng/dl 9.4
(0.2–1.6 nmol/liter) (0.3)
Aldosterone 5–90 ng/dl 5.1
(140–2500 pmol/liter) (141)
DHEA 26–375 ng/dl 14.4
(0.09–1.3 nmol/liter) (0.05)
PRA 2.35–37 g/literh 33
Urinary 17-ketosteroids Undetectable
All values are determined from plasma, except 17-ketosteroids from urine. DHEA, Dehydroepiandrosterone; PRA, plasma renin activity.
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mutations. B, Chromatograms showing the L157P, 629–630delCT, and L260P mutations identified from the three reported patients, compared
with normals. C, Family trees with the mutations and the size of the associated D8S536 allele. D, Ribbon diagram of the StAR protein based
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the StAR gene; D8S536, 85 kb downstream). Only D8S536
varied in our three families (Fig. 1C). L260P was always
associatedwithaD8S536allele92bpinlength.However,this
92-bp fragment was also identified with the normal and the
L157P allele in family II and was found to be present in 31%
(10 of 32 alleles) of the Swiss population. Nevertheless, the
obligate association of the L260P mutation with the 92-bp
alleleofD8S536indicatesthattheL260Pmutationinallthree
families of Swiss ancestry might originate from a common
ancestral allele.
Structural modeling of missense mutations
Based on the START domain of human MLN64 (12), the
mutated leucine at position 157 is a conserved residue that
lies within the -sheet 4 and forms part of the -barrel (Fig.
1D, green). The leucine at position 260 is a conserved residue
in the helix 4, which is thought to contribute directly to the
lipid tunnel harboring cholesterol. Together with previously
reported missense mutations in StAR (L169, R182, D203,
R217, A218, M225, L275) (Fig. 1D, yellow), mutations seem to
cluster around this lipid tunnel.
Functional studies
Totestthefunctionalconsequencesofthenewlyidentified
StAR mutations, we built vectors expressing the mutant
StAR proteins and compared their ability to promote preg-
nenolone production when transfecting nonsteroidogenic
COS-1 cells with either wild-type or mutant StAR and an
expression vector containing the fused cholesterol side chain
cleavage system (3, 11). In this assay, pregnenolone produc-
tion from cholesterol was only slightly higher with all three
novel StAR mutations (L157P, L260P, 629–630delCT) than
vector control (14.7–17.3 vs. 9.4%; P  0.05) (Fig. 2). In con-
trast, wild-type StAR promoted pregnenolone production
from endogenous cholesterol similar to StAR-independent
pregnenolone production from exogenously added 22R-hy-
droxycholesterol, a nonphysiological substrate for the side
chaincleavagesystemcrossingthemitochondrialmembrane
independent of StAR (positive control). Thus, the StAR mu-
tations identified (L157P, L260P, and 629–630delCT) are
fully responsible for lipoid CAH in the reported patients.
Discussion
The association between StAR mutations and lipoid con-
genital adrenal hyperplasia is well established (2). Defects in
theStARgenearerareandusuallyoccursporadically(5).The
only consistent genetic clusters identified to date are the
Q258XmutationintheJapaneseandKoreanpopulations(13,
14),theR182LmutationamongPalestinianArabs(2),andthe
R182H mutation in eastern Saudi Arabians (7). Our report of
three unrelated patients with Swiss ancestry carrying either
a homozygous or compound heterozygous L260P mutation
expands the geographic distribution of this condition and
establishes a new prevalent mutation for the Swiss popula-
tion. Intriguingly, one may wonder whether Prader’s orig-
inal Swiss lipoid CAH patient also had this precise genetic
defect (1). However, because this patient died more than 60
yr ago, we were neither able to get his DNA for analysis nor
foundfamilymemberswhocouldhavebeeninvestigatedfor
heterozygosity. Nevertheless, our microsatellite studies fa-
vor a possible founder effect for the L260P mutation in the
Swiss population.
Analysis of truncated StAR proteins have shown that the
on the START domain of human MLN64 [2.2 Å resolution, protein database reference ID:1EM2 (12)]. The four -helices are shown in red and
nine-sheetsareshowninblue.Left,LipidbindingtunneloftheSTARTdomainisformedbytheU-shaped-barrelandhelix-4.Right,Rotated
image to show the lower entrance of the tunnel. The positions of the two mutated leucines in these patients (L157, L260) are shown in green.
Leucine at position 157 is a conserved residue within 4 and forms part of the -barrel. Leucine at position 260 is a conserved residue in helix-4
and is thought to contribute directly to the lipid tunnel. For comparison, previously reported missense mutations in StAR (L169, R182, D203,
R217, A218, M225, L275) are shown in yellow.
FIG. 2. Functional activity of mutant vs. wild-type StAR. A, Ability
to produce pregnenolone from cholesterol was tested for wild-type
(WT) and mutant StAR in vitro. COS-1 cells were transiently trans-
fected with expression vectors for the side chain cleavage system (F2)
and either wild-type or mutant StAR (3). Pregnenolone concentration
was determined by RIA. Empty vector control (Ve) was used as a
negativecontrol,andtheStAR-independentsubstrate22(R)-hydroxy-
cholesteroladdedtothecellculturemediaprovidedapositivecontrol.
B and C, Equal gene expression of wild-type vs. mutant StAR was
assessed by semiquantitative RT-PCR using RNA extracted from
COS-1cells36haftertransfection(B)andbyWesternblotusingStAR
antibody (C). Data represent the mean  SEM from three independent
experiments, each performed in triplicate. GAPDH, Glyceraldehyde-
3-phosphate dehydrogenase; P450scc, P450 side-chain cleavage. M,
Marker; CO, negative control for PCR.
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deletion of only 10 carboxyl-terminal amino acids reduces
StAR activity by half (15), and deletion of 28 carboxyl-ter-
minal amino acids eliminates activity completely (3). By con-
trast, at least 62 amino-terminal amino acids can be removed
without functional consequences (15). All missense muta-
tions described to date are clustered in exons 4–7 and lie in
the carboxyl-terminal half of the molecule (5, 16). In func-
tional studies (3, 11), only the M225T mutation was found to
have partial activity of 29%, whereas all other reported mis-
sense mutations had activities of less than 10% (13, 16). Thus,
because StAR-independent pregnenolone production in this
system is about 14% (2), all reported missense mutations but
M225T lack StAR activity. Similarly, the L260P and L157P
mutations described here both affect highly conserved res-
idues of the carboxyl-terminal StAR domain and cause loss
of StAR activity. This complete loss of functional activity of
most StAR mutations in vitro contrasts with clinical variation
in disease severity and age of presentation. Onset of symp-
toms in our patients ranged from 2.5 to 5.5 months but may
occur from 1 to 14 months in patients carrying R182H (7).
This poor correlation between clinical findings and in vitro
studies of StAR mutations may be explained by limited sen-
sitivity of the functional assay, interindividual variability of
StAR-independent steroidogenesis, or variable expression of
StAR-like molecules, such as MLN64 or Star D4–8 (7).
Recently the crystal structure of the StAR-related lipid
transferdomainMLN64hasbeendetermined,andaputative
lipid-binding tunnel that shuttles cholesterol through the
intermembranous space of the mitochondria has been iden-
tified(12, 17). This lipid-binding tunnel is formed by a U-
shaped -barrel and helix-4 (Fig. 3). Using a modeling ap-
proach, we have shown that the leucine at position 157 is a
conserved residue within -sheet-4 that forms part of the
-barrel, whereas the leucine at position 260 is a conserved
residueinhelix-4thatisthoughttocontributedirectlytothe
lipid tunnel (12). These missense mutations in StAR lie
within the lipid-tunnel region and presumably impair func-
tion by causing abnormal protein folding and reduced cho-
lesterol binding. Furthermore, these cases show how natu-
rally occurring missense mutations found in patients with
lipoid CAH can provide information about critical structural
domains of the StAR protein.
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